Propanc Biopharma Inc (PPCB)

$2.87 -5.13 (-64.13%)
Market Cap 155,000.00
Revenue (ttm) 0.00
Net Income (ttm) -1.82M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.03
Volume 489,547
Avg Vol 2,732
Day's Range N/A - N/A
Shares Out 19,000.00
Stochastic %K 94%
Beta 2.78
Analysts Strong Buy
Price Target $12.50

Company Profile

Propanc Biopharma, Inc., a development-stage biopharmaceutical healthcare company, engages in the development of cancer treatments for patients with pancreatic, ovarian, and colorectal cancers in Australia. Its lead product candidate is PRP, an intravenous injection proenzyme treatment designed as a therapeutic option in cancer treatment and prevention which has completed pre-clinical studies. The company has a research and collaboration agreement with the University of Jaén, to undertakes the r...

Industry: Biotechnology
Sector: Healthcare
Phone: 61 3 9882 0780
Fax: 61 3 9882 9969
Address:
302, 6 Butler Street, Camberwell, Australia
IR_propancbiopharma
IR_propancbiopharma Jun. 24 at 2:04 PM
$PPCB Biotechnology companies often work with specialized manufacturing partners known as Contract Development and Manufacturing Organizations, or CDMOs. Scientific research is only one part of the development process. Before a therapy can be studied in humans, manufacturing processes, quality standards, and operational readiness all need to be established. Our recent visit to a European CDMO was part of the work required to prepare PRP for the next stage of development. Moving a therapy toward clinical studies involves much more than research alone, and manufacturing preparation is an important part of that process. Follow us as we continue sharing the milestones supporting PRP's development pathway toward our planned Phase 1b First-In-Human study.
0 · Reply
Zackpedia
Zackpedia Jun. 23 at 3:23 PM
$PPCB Down to 1.2! You could’ve sold when I alerted…
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 18 at 9:06 PM
$PPCB yeah best to assume 1.20 area. need some bottom wicks. ATL then big reverse I hope
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Jun. 18 at 4:54 PM
$PPCB Many investors first hear about a biotechnology company when a clinical study is announced. What often goes unseen is the work required before a therapy can reach that stage. Scientific publications, patent development, manufacturing preparation, supplier relationships, and study planning all play an important role in moving a program from research into the clinic. Over recent years, we have continued building that foundation through scientific publications, patent filings, academic collaborations, manufacturing preparation, and partnerships supporting the future clinical development of PRP. Together, these milestones have helped position the program for its next stage of development.
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 18 at 2:50 PM
$PPCB I don't think it'll come down to 1.18 but it very much could
0 · Reply
JOHNNY_DANGER
JOHNNY_DANGER Jun. 18 at 2:49 PM
$PPCB probably gonna run to 10.00 plus.
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 18 at 2:34 PM
$PPCB gap closed. alert alert... now how fast can it do a switcheroo
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 9:06 PM
$PPCB $DSY $YMAT $RGNT $WCT
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 8:41 PM
$PPCB will it come down to $1.50? then $11.50? probably
0 · Reply
SA449
SA449 Jun. 17 at 8:24 PM
$PPCB " TO THE TOP "
0 · Reply
Latest News on PPCB
Propanc CEO visits European manufacturer ahead of drug production plan

2026-06-16T13:41:11.000Z - 8 days ago

Propanc CEO visits European manufacturer ahead of drug production plan

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Jun 16, 2026, 8:45 AM EDT - 8 days ago

Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

Propanc Biopharma announces $5M share repurchase program

2026-06-11T13:14:59.000Z - 13 days ago

Propanc Biopharma announces $5M share repurchase program

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Jun 11, 2026, 8:30 AM EDT - 13 days ago

Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Jun 2, 2026, 5:30 AM EDT - 22 days ago

Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

May 20, 2026, 8:45 AM EDT - 5 weeks ago

Propanc Biopharma's CEO Forecasts New Medical Breakthroughs in the Fight Against Pancreatic Cancer Over the Next Decade

Propanc Biopharma engages European CDMO for GMP production of PRP

2026-05-19T13:16:34.000Z - 5 weeks ago

Propanc Biopharma engages European CDMO for GMP production of PRP

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

May 19, 2026, 8:45 AM EDT - 5 weeks ago

Propanc Biopharma Engages European CDMO for GMP Production of PRP for Phase 1b, FIH Study in 30 – 40 Advanced Cancer Patients

Propanc Biopharma Inc trading halted, news pending

2026-05-15T23:51:01.000Z - 5 weeks ago

Propanc Biopharma Inc trading halted, news pending

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

May 15, 2026, 8:45 AM EDT - 5 weeks ago

Propanc Biopharma Provides Corporate Update and Reports Third Quarter 2025/26 Results

Propanc Biopharma announces 1-for-25 reverse stock split

2026-05-14T09:34:08.000Z - 5 weeks ago

Propanc Biopharma announces 1-for-25 reverse stock split

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

May 13, 2026, 10:00 PM EDT - 6 weeks ago

Propanc Biopharma Implements Reverse Stock Split to Support Continued Nasdaq Listing and Growth Plans

Propanc Biopharma files to sell 15M shares of common stock for holders

2026-04-10T21:35:15.000Z - 2 months ago

Propanc Biopharma files to sell 15M shares of common stock for holders

Propanc Biopharma signs multi-year collaboration with Spanish universities

2026-03-24T13:11:19.000Z - 3 months ago

Propanc Biopharma signs multi-year collaboration with Spanish universities

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Mar 24, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Executes Multi-Yr, Anti-Aging & Cancer Research Collaboration with the Universities of Jaén and Granada, Spain

Propanc Biopharma announces highlights of PRP

2026-03-12T13:04:12.000Z - 3 months ago

Propanc Biopharma announces highlights of PRP

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Mar 12, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Targets $3B+ Pancreatic Cancer Market with PRP: 85%+ Tumor Inhibition in Breakthrough Proenzyme Therapy

Propanc Biopharma executes service agreement with FyoniBio

2026-03-10T12:51:18.000Z - 3 months ago

Propanc Biopharma executes service agreement with FyoniBio

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Mar 10, 2026, 8:45 AM EDT - 3 months ago

Propanc Biopharma Executes Service Agreement with FyoniBio to Establish & Validate Pharmacokinetics Assay for Phase 1b First-In-Human Study

Propanc Biopharma highlights potential of lead asset PRP

2026-03-03T13:59:37.000Z - 4 months ago

Propanc Biopharma highlights potential of lead asset PRP

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Mar 3, 2026, 8:45 AM EST - 4 months ago

Propanc Biopharma's Lead Asset PRP Shows >85% Tumor Growth Inhibition in Preclinical Pancreatic Models

Propanc Biopharma provides corporate update

2026-02-18T13:50:25.000Z - 4 months ago

Propanc Biopharma provides corporate update

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Feb 18, 2026, 8:45 AM EST - 4 months ago

Propanc Biopharma Provides Corporate Update and Reports Half Yearly 2025/26 Results

Propanc Biopharma highlights potential of lead proenzyme therapy

2026-02-05T13:50:26.000Z - 4 months ago

Propanc Biopharma highlights potential of lead proenzyme therapy

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Feb 5, 2026, 8:45 AM EST - 4 months ago

Propanc Biopharma Unveils PRP: A Game-Changing Proenzyme Therapy Poised to Challenge Standard Cancer Treatments in the $3+ Billion Pancreatic Cancer Market

Propanc Biopharma files to sell 7M shares of common stock for holders

2026-02-02T22:35:25.000Z - 5 months ago

Propanc Biopharma files to sell 7M shares of common stock for holders

Propanc Biopharma files fourth patent application with IP Australia

2026-01-27T13:50:56.000Z - 5 months ago

Propanc Biopharma files fourth patent application with IP Australia

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Jan 27, 2026, 8:45 AM EST - 5 months ago

Propanc Biopharma Accelerates IP Momentum: Files Fourth Provisional Patent Application in Just Two Months – Strengthening Global Protection for Breakthrough Proenzyme Formulations

Propanc Biopharma files new provisional patent application with IP Australia

2026-01-20T13:56:58.000Z - 5 months ago

Propanc Biopharma files new provisional patent application with IP Australia

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Jan 20, 2026, 8:45 AM EST - 5 months ago

Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia

Propanc Biopharma announces update on pancreatic cancer research

2026-01-15T13:50:32.000Z - 5 months ago

Propanc Biopharma announces update on pancreatic cancer research

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Jan 15, 2026, 8:45 AM EST - 5 months ago

Propanc Biopharma Explains How PRP Could Impact Pancreatic Cancer

Propanc Biopharma issues letter to shareholders

2026-01-13T13:56:11.000Z - 5 months ago

Propanc Biopharma issues letter to shareholders

Propanc Biopharma Provides Shareholder Update

Jan 13, 2026, 8:45 AM EST - 5 months ago

Propanc Biopharma Provides Shareholder Update

Propanc Biopharma publishes impact of proenzymes on PDAC fibroblasts

2025-12-22T12:05:46.000Z - 6 months ago

Propanc Biopharma publishes impact of proenzymes on PDAC fibroblasts

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Dec 22, 2025, 7:00 AM EST - 6 months ago

Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal

Propanc Biopharma plans to investigate ‘mesenchymal drift’

2025-12-04T13:50:28.000Z - 7 months ago

Propanc Biopharma plans to investigate ‘mesenchymal drift’

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Dec 4, 2025, 8:45 AM EST - 7 months ago

Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Dec 1, 2025, 8:45 AM EST - 7 months ago

Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Nov 17, 2025, 8:45 AM EST - 7 months ago

Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Nov 10, 2025, 8:45 AM EST - 8 months ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company's R&D Pipeline

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

Nov 4, 2025, 7:00 AM EST - 8 months ago

Propanc Biopharma, Inc. Pursues Strategic Acquisition Plan Targeting Digital Asset Treasury (DAT) Companies Trading Below Market Cap to Net Asset Value (MNAV)

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 5:45 PM EDT - 9 months ago

CORRECTION: Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Oct 15, 2025, 8:45 AM EDT - 9 months ago

Propanc Biopharma Announces Strategic Financing Agreement of up to $100 Million with Hexstone Capital

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Oct 7, 2025, 8:45 AM EDT - 9 months ago

Propanc Reports End of Fiscal Year Highlights and Outlines Therapeutic Development & $100M+ Digital Asset Treasury Strategy

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Sep 17, 2025, 8:45 AM EDT - 10 months ago

Propanc Biopharma Receives Certificate of Grant for “Proenzyme Composition” Patent from US Patent & Trademark Office

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Sep 2, 2025, 9:00 AM EDT - 10 months ago

Propanc Biopharma Announces Plan to Acquire $100 Million of Ethereum

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Aug 19, 2025, 8:30 AM EDT - 11 months ago

Propanc Biopharma Announces Closing of Public Offering and Uplisting to NASDAQ

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

Aug 14, 2025, 11:00 PM EDT - 11 months ago

Propanc Biopharma Announces Nasdaq Uplisting and Pricing of $4 Million Public Offering

IR_propancbiopharma
IR_propancbiopharma Jun. 24 at 2:04 PM
$PPCB Biotechnology companies often work with specialized manufacturing partners known as Contract Development and Manufacturing Organizations, or CDMOs. Scientific research is only one part of the development process. Before a therapy can be studied in humans, manufacturing processes, quality standards, and operational readiness all need to be established. Our recent visit to a European CDMO was part of the work required to prepare PRP for the next stage of development. Moving a therapy toward clinical studies involves much more than research alone, and manufacturing preparation is an important part of that process. Follow us as we continue sharing the milestones supporting PRP's development pathway toward our planned Phase 1b First-In-Human study.
0 · Reply
Zackpedia
Zackpedia Jun. 23 at 3:23 PM
$PPCB Down to 1.2! You could’ve sold when I alerted…
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 18 at 9:06 PM
$PPCB yeah best to assume 1.20 area. need some bottom wicks. ATL then big reverse I hope
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Jun. 18 at 4:54 PM
$PPCB Many investors first hear about a biotechnology company when a clinical study is announced. What often goes unseen is the work required before a therapy can reach that stage. Scientific publications, patent development, manufacturing preparation, supplier relationships, and study planning all play an important role in moving a program from research into the clinic. Over recent years, we have continued building that foundation through scientific publications, patent filings, academic collaborations, manufacturing preparation, and partnerships supporting the future clinical development of PRP. Together, these milestones have helped position the program for its next stage of development.
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 18 at 2:50 PM
$PPCB I don't think it'll come down to 1.18 but it very much could
0 · Reply
JOHNNY_DANGER
JOHNNY_DANGER Jun. 18 at 2:49 PM
$PPCB probably gonna run to 10.00 plus.
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 18 at 2:34 PM
$PPCB gap closed. alert alert... now how fast can it do a switcheroo
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 9:06 PM
$PPCB $DSY $YMAT $RGNT $WCT
0 · Reply
Sw1ngb0t
Sw1ngb0t Jun. 17 at 8:41 PM
$PPCB will it come down to $1.50? then $11.50? probably
0 · Reply
SA449
SA449 Jun. 17 at 8:24 PM
$PPCB " TO THE TOP "
0 · Reply
Eruption
Eruption Jun. 17 at 3:27 PM
$PPCB i hope not too many here got badly hurt by the recent pump & dump. I tried to warn as much as possible.
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Jun. 17 at 1:36 PM
$PPCB Scientific progress does not happen in isolation. Conferences, keynote presentations, and academic collaborations allow researchers to share findings, challenge assumptions, and build upon existing knowledge. Recent discussions at the University of Granada focused on aging,regeneration, and cell biology, fields that continue to influence research across cancer and other chronic diseases. Propanc CEO James Nathanielszattended the event alongside the company's academic collaborators from the Universities of Granada and Jaén, providing an opportunity to engage directly with current scientific thinking in these areas. These are also areas that continue to inform our own research efforts as we advance PRP toward our planned Phase 1b First-In-Human study.
0 · Reply
SA449
SA449 Jun. 17 at 11:37 AM
$PPCB Patience and execution is a key here! 🚀📈💰🤑
0 · Reply
SuperGreenToday
SuperGreenToday Jun. 16 at 6:14 PM
$PPCB
0 · Reply
SA449
SA449 Jun. 16 at 4:40 PM
$PPCB " TO THE TOP " Extremely Bullish 🚀🗻🪙💰🤑
0 · Reply
IR_propancbiopharma
IR_propancbiopharma Jun. 16 at 2:09 PM
$PPCB One of the biggest challenges in cancer treatment is not the initial tumor. It is recurrence. Researchers believe that a small population of cells known as cancer stem cells may play an important role in helping tumors return and spread after treatment. This area of research continues to receive significant attention because recurrence remains one of the most difficult problems in oncology. Understanding the biological mechanisms that contribute to cancer progression may help researchers identify new approaches to preventing tumors from returning after treatment. At Propanc, our research program has focused on biological mechanisms associated with cancer recurrence and metastasis for more than 17 years. That work has contributed to scientific publications, patentable discoveries, and the continued development of PRP as we advance toward our planned Phase 1b First-In-Human study in advanced cancer patients.
0 · Reply
SA449
SA449 Jun. 16 at 1:45 PM
$PPCB " TO THE TOP " Extremely Bullish 🚀🗻🪙💰🤑
0 · Reply
dr_ladybananas
dr_ladybananas Jun. 16 at 1:37 PM
$PPCB
0 · Reply
SA449
SA449 Jun. 16 at 1:24 PM
$PPCB
0 · Reply
Stock_Catcher
Stock_Catcher Jun. 16 at 12:47 PM
$PPCB Propanc Biopharma’s CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study
0 · Reply
SA449
SA449 Jun. 16 at 6:41 AM
$PPCB
0 · Reply
wesfabian1
wesfabian1 Jun. 15 at 7:58 PM
$PPCB some would find this appealing
0 · Reply